Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

Research

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k872 (Published 21 March 2018) Cite this as: BMJ 2018;360:k872

Data supplement

Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study
Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study
- Abstract
- Fulltext
Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol
- Abstract
- Fulltext
- PDF
Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study
- Abstract
- Fulltext
- PDF
Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study
- Abstract
- Fulltext
- PDF
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults
- Abstract
- Fulltext
- PDF
Linagliptin-associated bullous pemphigoid treated with rituximab
- Abstract
- Fulltext
- PDF
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
- Abstract
- Fulltext
- PDF
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
- Abstract
- Fulltext
- PDF